Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma  by Chen, Long et al.
www.elsevier.com/locate/humpath
Human Pathology (2015) 46, 120–128Original contributionClassification of microvascular patterns via
cluster analysis reveals their prognostic
significance in glioblastoma☆,☆☆Long Chen MDa,b, Zhi-Xiong Lin MD, PhD c,⁎, Guo-Shi Lin MDc, Chang-Fu Zhou MDc,
Yu-Peng Chen MDd, Xing-Fu Wang MDd, Zong-Qing Zheng MDc
aTumor Invasion Microecological Laboratory, Fujian Medical University, Fuzhou 350005, China
bIntensive Care Unit, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
cDepartment of Neurosurgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
dDepartment of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
Received 15 July 2014; revised 1 October 2014; accepted 3 October 2014o
☆
D
S
a
3
h
0
bKeywords:
Glioblastoma;
Angiogenesis;
Morphology;
Microvascular patterns;
Cluster analysis;
PrognosisSummary There are limited researches focusing on microvascular patterns (MVPs) in human glioblastoma
and their prognostic impact. We evaluated MVPs of 78 glioblastomas by CD34/periodic acid–Schiff dual
staining and by cluster analysis of the percentage of microvascular area for distinct microvascular
formations. The distribution of 5 types of basic microvascular formations, that is, microvascular sprouting
(MS), vascular cluster (VC), vascular garland (VG), glomeruloid vascular proliferation (GVP), and
vasculogenicmimicry (VM),was variable. Accordingly, cluster analysis classifiedMVPs into 2 types: type I
MVP displayed prominent MSs and VCs, whereas type II MVP had numerous VGs, GVPs, and VMs. By
analyzing the proportion of microvascular area for each type of formation, we determined that glioblastomas
with few MSs and VCs had many GVPs and VMs, and vice versa. VG seemed to be a transitional type of
formation. In case of type I MVP, expression of Ki-67 and p53 but not MGMT was significantly higher as
compared with those of type IIMVP (P b .05). Survival analysis showed that the type ofMVPs presented as
an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) (both P b
.001). Type IIMVPhad amore negative influence on PFS andOS than did type IMVP.We conclude that the
heterogeneous MVPs in glioblastoma can be categorized properly by certain histopathologic and statistical
analyses and may influence clinical outcome.
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y-nc-nd/3.0/).1. IntroductionGlioblastoma, the most common malignant primary brain
tumor in adults, results in disproportionately high morbidity
and mortality. Despite optimized treatment strategies and
evolving standards of care, the median overall survival (OS)
for patients with cancer in this setting is only 12 to 15 monthsrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/
Table 1 Clinical and histopathologic features of 78 patients
with primary supratentorial glioblastoma
Clinical and histopathologic features n = 78
Sex, male/female 47/31
Age (y), median (range) 57.8 (23.6-82.1)
Preoperative KPS, median (range) 80 (40-100)
Radiotherapy a, yes/no 39/39
Chemotherapy b, for b6 cycles/≥6 cycles 27/51
12-mo PFS rate (%) 34.2
PFS (wk), median (95% CI) 42.0 (34.8-49.2)
No tumor recurrence c 5
12-mo OS rate (%) 67.1
OS (wk), median (95% CI) 54.7 (47.8-61.6)
Alive at last observation c 9
MGMT (%), median (95% CI) 28 (0-61)
Ki-67 (%), median (95% CI) 31 (3-88)
p53 (%), median (95% CI) 21 (0-92)
Abbreviations: KPS, Karnofsky performance status; PFS, progression-
121Microvascular patterns in glioblastoma[1]. Glioblastomas are highly vascularized tumors character-
ized by an abundance of disorganized microvessels and an
aggressive proliferation of endothelial cells (ECs) and
pericytes [2]. The prognosis of patients may be due to these
morphologically heterogeneous microvessels and the accom-
panying expression of angiogenic proteins [3,4]. Although
microvascular density (MVD) and microvascular area (MVA)
are bona fide predictive factors for patient outcome in the
major tumors [5–8], some believe that the morphometric
complexity of vasculature in glioblastoma can be poorly
characterized using these quantitative indexes [3]. Recently,
another parameter, microvascular pattern (MVP), emphasizing
the angiogenic pathogenesis, has been focused on for its
influence on patients' survival with glioblastoma, whereas the
present evidence was limited and even inconsistent [9–11].
For this reason, we classifiedMVPs in glioblastoma on basis of
their distinct characteristics via cluster analysis to investigate
their relevance to clinical outcomes.free survival; CI, confidence interval; OS, overall survival.
a Delivered as 60Gy/30 fractions to the resection site with a 2- to 3-cm
margin within 5 to 6 weeks after surgery.
b For adjuvant regimen, oral temozolomide was administered at a
daily dose of 150 to 200 mg/m2 for 5 days every 28 days (the first cycle
began within 7-10 days after surgery); for concomitant regimen,
temozolomide was administered at a daily dose of 75 mg/m2 for 21
days every 28 days.
c Three patients died of causes unrelated to glioblastoma, and one
patient lost to follow-up.2. Materials and methods
2.1. Clinical details
This study enrolled 78 adult patients with primary supra-
tentorial glioblastoma who underwent initial surgery between
March 2007 and August 2013 at the First Affiliated Hospital of
FujianMedical University. All patients receivedmicroscopically
extensive resection (N90%) verified by postoperative magnetic
resonance imaging (MRI), without any preoperative adjuvant
therapy (radiotherapy and/or chemotherapy). The tumor speci-
mens were reviewed and confirmed in accordance with the
current World Health Organization criteria [12]. None of them
displayed oligodendroglial features. Postoperative adjuvant
therapies were administered properly depending on the
individual tumor responses and each patient's clinical status.
Follow-up information was updated every 2 months via a clinic
visit, a telephone interview, or review of a death certificate. The
date of the last observation was February 1, 2014, with a median
follow-up period of 12.8 months (range, 4.0-37.7 months). The
observed clinical characteristics are shown in Table 1.
2.2. Dual staining for CD34 and periodic acid–Schiff
Sections were cut at a thickness of 4 μm from routinely
prepared, formalin-fixed, paraffin-embedded blocks of
tumor tissue. CD34/periodic acid–Schiff (PAS) dual
staining was implemented according to the method
described by Yue and Chen [13]. For CD34 staining,
we used a mouse monoclonal anti-CD34 antibody (clone
QBEnd 10, 1:50; Dako, Glostrup, Denmark). Adult liver
tissues were applied as positive controls, whereas the
phosphate-buffered saline solution (0.01 M, pH 7.2) instead
of the CD34 antibody or periodic acid was used for negative
control. In addition, microvessels from nonneoplasic braintissue adjacent to tumor served as internal morphological
controls (Fig. 1A).
2.3. Assessment of MVPs
Three trained investigators (L. C., C. F. Z., and X. F. W.)
who were blinded to the clinical data used a multiheaded
microscope to assess MVPs.
Five types of microvascular formations, as described by
Birner et al [9] and Yue and Chen [13], were identified in
glioblastomas. For CD34-positive microvessels, 4 types of
formations were defined: (1) microvascular sprouting (MS),
defined as delicate capillary-like microvessels resembling
those seen during classic angiogenesis, distributed evenly
throughout the major parts of vital tumor tissue (Fig. 1B);
(2) vascular cluster (VC), defined as distinct focal aggrega-
tions of vessels (≥3) without connective stroma (Fig. 1C);
(3) vascular garland (VG), defined as clustered vessels
arranged in garland-like formation, with or without connec-
tive stroma, frequently located around necrotic tissue
(Fig. 1D); and (4) glomeruloid vascular proliferation
(GVP), defined as clustered vessels (≥3) ensheathed by
connective stroma (Fig. 1E). Stained lumen or separate
CD34-positive cell was regarded as a single countable
microvessel, with the exception of vessel with muscular
walls. For hollow channels or networks that were CD34-
negative and PAS-positive, vasculogenic mimicry (VM) was
Fig. 1 A-F,Microvascular formations in glioblastoma. A,Microvessels in the surrounding nonneoplasic brain tissue. B,MS: delicate capillary-
like microvessels resembling classic angiogenesis. C, VC: distinct focal aggregations of vessels (≥3) without connective stroma. D, VG: clustered
vessels with or without connective stroma arranged in garland-like formation. E, GVP: clustered vessels (≥3) ensheathed by connective stroma.
F, VM: characterized as CD34-PAS+ patterns with hollow channels or networks. CD34-PAS dual staining, scale bar: A-C, E, and F, 100 μm;
D, 200 μm. G and H, The definition of microvascular boundaries. G, When PAS staining was obvious, the outlines of PAS+ matrices served as
boundaries. H, When PAS staining was weak, the outlines of CD34+ cells or lumina were regarded as boundaries.
122 L. Chen et al.considered as the fifth type of formation (Fig. 1F). Since
there might be several intermediate formations due to the
mussy angiogenesis in glioblastoma, especially between the
markedly proliferative clustered vessels with connective
stroma in VG and GVP, the following rule was supplement-ed to distinguish them: The clustered vessels with connective
stroma were considered as 1 GVP when their nuclear layer
(defined as the number of nuclei in their minor axis) was
at least 4 [14], or they were judged to be components of
a VG.
123Microvascular patterns in glioblastomaHistopathologic images were transferred to a computer
for further processing and analysis using Image-Pro Plus for
Windows, version 6.0 (Media Cybernetics, Silver Spring,
MD). The program was calibrated with a standard scale.
To calculate the area occupied by tumor microvessels, the
boundaries of the vessels were traced by manually moving
the cursor over the outlines of PAS-positive matrices
(Fig. 1G). For samples with faint PAS staining, we measured
the outlines of CD34-positive cells or lumina (Fig. 1H).
In consideration of the uneven distribution of microvessels
in tumor tissues [10], a 2-step, “multi-hotspot” assessment was
achieved. First, each section displaying dual staining of CD34
and PASwas scanned at lowmagnification (×40), and all areas
with a high density of distinctly highlighted microvessels
(a “hotspot”) were screened and encoded, free of surgical
wound changes. In the second step, 10 of the encoded hotspots
were chosen at random and sampled evenly. The areas
occupied by microvessels with different formations were
determined by scanning at a total magnification of ×200within
an examination area of 0.36 mm2 for each hotspot. The mean
of the 10 areas was then calculated to obtain MVA. Since the
absolute value of MVA may vary with the area examined, the
percentage of MVA (%MVA) was calculated by using the
following formula: %MVA= (MVA/examination area) × 100.
We also calculated the proportion of MVA with a certain
microvascular formation (Proportion) by using the following
formula: Proportion = (MVAof a certain formation/totalMVA
of all 5 formations) × 100. To ensure the reproducibility of our
results, each assessment was repeated 3 times, and the average
of the 2 most similar values was taken as a confirmation.
2.4. Immunohistochemical analyses
Serial sections from matched specimens were selected
for immunohistochemistry. To explore if there were any
correlations between MVPs and tumor cellularity, the
following mouse monoclonal antibodies were used with
standard protocols [15,16]: MGMT (clone MT3.1, 1:100;
Santa Cruz Biotechnology, Santa Cruz, CA), Ki-67 (clone
MIB-1, 1:100; Dako), and p53 (clone DO-7, 1:50; Dako). As
positive controls, human kidney tissue, tonsil, and ovarian
carcinoma were used, respectively. Negative controls were
fulfilled by omission of the primary antibody. Expression of
molecular markers was scored in percentage by counting the
labeled nuclei in 500 tumor cells of the most immunoreactive
area (Fig. 2). Based on the estimation, MGMT was judged as
“low” (b30%) or “high” (≥30%) [15], and tumors with more
than 10% stained cells were considered as p53 positive [16].2.5. Statistical analysis
The %MVA of each type of microvascular formation was
subjected to K-means clustering to partition the tumor samples
into several groups (or clusters, more precisely). Because the
number of clusters is an input parameter, the analysis wasperformed 3 times, with 2, 3, or 4 clusters set as the input to
obtain the optimal number. The validity and reproducibility of
clustering were tested by Fisher discriminant analysis.
The differences between groups were tested for signifi-
cance by the Kruskal-Wallis and Mann-Whitney tests
because the raw data were not normally distributed.
Progression-free survival (PFS) was defined as the time
between the date of the initial surgery and that of
documented tumor recurrence, as revealed by either MRI
or the occurrence of new neurologic symptoms. OS was
defined as the time between the date of surgery and that of
the patient's tumor-related death. For patients who did not
experience recurrence or death, PFS and OS were censored at
the end of the observation period. Death from a cause other
than glioblastoma and loss of contact were also considered as
censored events. The survival probabilities were computed
by using the Kaplan-Meier method. Log-rank test and Cox
proportional hazards regression model were used for
univariate and multivariate analyses of PFS and OS. MVP,
selected clinical variables (age, preoperative Karnofsky
performance status [KPS],, and adjuvant therapy), and
expression of molecular markers (MGMT, Ki-67, and p53)
were entered into Cox regression model with forward
selection. The cutoff points for age, KPS, and expression
of Ki-67 were defined on basis of the median values. Hazard
ratios (HRs) and their corresponding 95% confidence
intervals (95% CIs) calculated are given. All calculations
were accomplished with SPSS for Windows, version 19.0
(SPSS, Chicago, IL). Statistical significance was set at the
level of P b .05.3. Results
3.1. Classification of MVPs in glioblastoma
MVPs were evaluated in all 78 glioblastomas. There was a
variable prominence of the 5 types of microvascular
formations (MS, VC, VG, GVP, and VM). This finding
illustrates the heterogeneity of MVPs (Table 2). With the aim
of selecting an appropriate classification for MVPs, we
performed the cluster analysis 3 times, with 2, 3, or 4 clusters
as the input parameter. Although all 3 values (Table 3) could
differentiate MVPs with distinct characteristics, we regarded a
2-cluster classification system as optimal for the current study
because of its simplicity and practicability on clinical
application. We hypothesized that 2 types of MVPs may
exist in glioblastoma, one (type I) comprised primarily of MSs
and VCs and the other (type II) with many VGs, GVPs, and
VMs (Fig. 3A). By analyzing the proportions of the 2 types,we
determined that glioblastomas with few MSs and VCs had a
substantial number of GVPs and VMs, and vice versa. VG
seemed to be a transitional type of formation (Fig. 3B).
The tumors in 56 patients (71.8%) had a type I MVP, whereas
those in the rest 22 patients (28.2%) got a type II MVP.
Fig. 2 The expression of MGMT, Ki-67 and p53 in glioblastoma. A, MGMT low expression (b30%). B, MGMT high expression (≥30%).
C, Ki-67 low expression (≤30%). D, Ki-67 high expression (N30%). E, p53 negative (≤10%). F, p53 positive (N10%). Scale bar: 100 μm.
124 L. Chen et al.To verify the accuracy of our results and to develop a
method that would allow us to predict the pattern of tumors
analyzed in future, we generated a discriminant function
including the %MVA of all 5 microvascular formations:
D ¼ −0:333%MVAMS−0:124%MVAVC þ 0:076
%MVAVG þ 0:267%MVAGVP þ 0:458
%MVAVM−1:443Table 2 Characteristics of MVPs in the overall cohort
Microvascular
formations
Cases,
positive/
negative
%MVA (%),
median (range)
Proportion (%),
median (range)
MS 65/13 0.68 (0.00-2.20) 14.40 (0.00-100.00)
VC 43/35 0.63 (0.00-2.43) 3.10 (0.00-75.03)
VG 54/24 1.51 (0.00-6.53) 15.14 (0.00-78.65)
GVP 51/27 3.52 (0.00-26.86) 50.97 (0.00-91.79)
VM 11/67 0.00 (0.00-1.15) 0.00 (0.00-5.06)
Abbreviations: MVP, microvascular pattern; MVA, microvascular area;
MS, microvacular sprouting; VC, vascular cluster; VG, vascular gland;
GVP, glomeruloid vascular proliferation; VM, vasculogenic mimicry.D = 0.890 was the critical value and corresponded to an
unclassified case, D b 0.890 identified glioblastomas with type I
MVP, andD N 0.890 indicated those with type II MVP.
In the current data set, all 56 type I MVPs (100.0%) and
21 (95.5%) of 22 type II MVPs were correctly classified,
with a total accuracy rate of 98.7% (77/78).
3.2. Correlation of histologic features
The fraction of stained tumor cells for immunohistochem-
istry is presented in Table 1. Correlating with MVPs, we
observed that the expression of Ki-67 (P = .010) and p53 (P =
.019) was significantly different between cases with the
classified MVPs (Table 4). However, there was no association
of the expression of MGMT with MVPs (P = .092), although
the portion of cells staining was higher in tumors with type II
MVP compared to those with type I MVP (Table 4).3.3. Survival analysis
The main outcome measures of this study, such as the 12-
month PFS/OS rate and median PFS/OS for the overall
Table 3 Classifications of MVPs with different number of clusters (K-means clustering analysis)
Microvascular
parameters
2-cluster 3-cluster
Type I (n = 56),
median (range)
Type II (n = 22),
median (range)
P a Type I (n = 46),
median (range)
Type II (n = 21),
median (range)
Type III (n = 11),
median (range)
P b
%MVA (%)
MS 0.79 (0.00-2.20) 0.54 (0.00-0.78) b.001 0.87 (0.00-1.78) 0.57 (0.00-2.20) 0.52 (0.00-0.68) b.001
VC 0.81 (0.00-2.43) 0.00 (0.00-0.85) .005 0.98 (0.00-2.43) 0.00 (0.00-1.76) 0.00 (0.00-0.73) .005
VG 0.66 (0.00-4.47) 3.16 (0.82-6.53) b.001 0.00 (0.00-4.47) 2.83 (1.50-6.53) 3.24 (0.82-4.76) b.001
GVP 0.54 (0.00-7.83) 14.77 (9.77-26.86) b.001 0.00 (0.00-5.12) 9.77 (5.55-13.86) 20.44 (15.67-26.86) b.001
VM 0.00 (0.00-0.22) 0.00 (0.00-1.15) .002 0.00 (0.00-0.22) 0.00 (0.00-0.74) 0.00 (0.00-1.15) .002
Proportion (%)
MS 21.98 (0.00-100.00) 2.45 (0.00-5.58) b.001 29.71 (0.00-100.00) 4.07 (0.00-21.88) 2.08 (0.00-3.36) b.001
VC 10.68 (0.00-75.03) 0.00 (0.00-6.05) .001 22.32 (0.00-75.03) 0.00 (0.00-14.31) 0.00 (0.00-3.17) .001
VG 13.83 (0.00-78.65) 16.90 (3.64-39.93) .305 0.00 (0.00-78.65) 23.01 (13.53-39.93) 11.80 (3.64-20.44) .002
GVP 22.31 (0.00-79.12) 77.31 (60.07-91.79) b.001 0.00 (0.00-79.12) 71.04 (51.87-81.28) 79.70 (76.45-91.79) b.001
VM 0.00 (0.00-3.43) 0.00 (0.00-5.06) .004 0.00 (0.00-3.43) 0.00 (0.00-3.42) 0.00 (0.00-5.06) .003
Abbreviations: MVA, microvascular pattern; MVA, microvascular area; MS, microvacular sprouting; VC, vascular cluster; VG, vascular gland; GVP,
glomeruloid vascular proliferation; VM, vasculogenic mimicry.
a Mann-Whitney test.
b Kruskal-Wallis test.
125Microvascular patterns in glioblastomacohort, are listed in Table 1. During the observation period,
69 patients (88.5%) died of their disease, 3 died of causes
unrelated to glioblastoma, and 1 was lost to follow-up.
Univariate analysis showed that the survival of patients with
tumor of type IIMVPwas significantly inferior to that of type I
MVP (P b .001; Table 4, Fig. 3C and D). Multivariate analysis
confirmed type II MVP as a significant prognostic factor for
both shorter PFS (HR, 4.573; 95% CI, 2.271-9.205; P b .001)
and OS (HR, 5.045; 95% CI, 2.396-10.620; P b .001),
independent of age, preoperative KPS, adjuvant therapy, and
expression of molecular markers (Table 5).4. DiscussionBy providing nutrients and oxygen for metabolism and
removal of resultant waste, angiogenesis is the propelling
force of tumor growth and metastasis [3]. Several quantita-
tive parameters, such as MVD, MVA, and microvascular
branching, have been widely studied in glioblastoma [7,9–
11,17–19]. However, only a few studies have focused
on MVPs and their prognostic impact, and the findings of
these studies are controversial [9–11]. In glioblastoma,
capillary-like MS and unevenly distributed, bizarre vascular
formations, such as GVP, VG, and VC, are commonly
observed [9]. In addition, recent reports have confirmed the
existence of VM in glioma [13,20,21]. The heterogeneity of
MVPs in glioblastoma may reflect the different mechanisms
of neoangiogenesis and is associated with patient prognosis
[22]. Therefore, characterization of MVPs could be mean-
ingful for guiding treatment.In most studies, MVD was the preferred parameter to
quantify the extent of tumor vascularization. Nevertheless, it
could hardly describe the morphometric complexity of
aberrant microvessels in malignant glioma, which are
characterized by a low abundance, large area, and multiple
lumina [19]. In contrast to that index, the prognostic value of
MVA has been increasingly emphasized in recent studies,
and MVA has been shown to be prognostically more
informative for patients with glioma [7,17,19]. In this study,
cluster analysis of the %MVA of distinct microvascular
formations in glioblastoma was used to classify MVPs into 2
types. We found that type I MVP consisted primarily of MSs
and VCs, whereas VGs, GVPs, and VMs predominated in
type II MVP. Besides, the results of our statistical analysis
indicated that significant differences in prognosis existed
between the 2 types of MVPs. Patients with tumor that
displayed type II MVP exhibited a poorer PFS and OS than
did those with type I MVP. Furthermore, a discriminant
function was established to demonstrate that the clustering
was feasible with high accuracy.
For translation to clinical application, the classification
criteria of MVPs should be stable and repeatable. In a
previous series [9,10], researchers distinguished a “classic”
vascular pattern in glioblastoma from a “bizarre” one with a
semiquantitative scoring system. A prolonged survival was
first observed in patients with tumor presenting classic
vascular pattern, yet the algorithm was subsequently found to
have poor interobserver agreement and not be consistently
associated with patient outcomes. In another study, the mean
survival of patients with tumor that revealed bizarre vascular
pattern was even longer than those that hit classic vascular
pattern, although the difference was not statistically
significant [11]. The lack of observer agreement in the
Table 3 Classifications of MVPs with different number of clusters (K-means clustering analysis)
4-cluster
Type I (n = 37),
median (range)
Type II (n = 19),
median (range)
Type III (n = 13),
median (range)
Type IV (n = 9),
median (range)
P b
%MVA (%)
0.87 (0.00-1.36) 0.62 (0.00-2.20) 0.56 (0.00-0.78) 0.35 (0.00-0.62) b.001
0.98 (0.00-2.22) 0.64 (0.00-2.43) 0.00 (0.00-0.85) 0.44 (0.00-0.73) .034
0.00 (0.00-4.47) 2.32 (0.62-3.55) 3.24 (2.05-6.53) 2.73 (0.82-4.76) b.001
0.00 (0.00-2.80) 5.55 (3.27-7.83) 11.73 (9.77-15.82) 20.53 (17.59-26.86) b.001
0.00 (0.00-0.21) 0.00 (0.00-0.22) 0.00 (0.00-1.04) 0.00 (0.00-1.15) .008
Proportion (%)
37.45 (0.00-100.00) 5.93 (0.00-21.88) 3.33 (0.00-5.58) 1.53 (0.00-2.86) b.001
33.03 (0.00-75.03) 6.14 (0.00-24.39) 0.00 (0.00-6.05) 1.80 (0.00-3.17) .006
0.00 (0.00-78.65) 23.01 (6.19-42.63) 20.68 (13.53-39.93) 11.45 (3.64-20.44) .001
0.00 (0.00-79.12) 59.52 (44.99-79.04) 75.43 (60.07-81.28) 81.21 (76.69-91.79) b.001
0.00 (0.00-3.43) 0.00 (0.00-2.63) 0.00 (0.00-5.06) 0.00 (0.00-4.26) .015
able 3 (continued)
Fig. 3 The correlation of different types of MVPs and survival in patients with glioblastoma. A, The %MVA (calculated by using the
formula: %MVA = [MVA/examination area] × 100) in the 2 types of MVPs. B, The proportion of MVA (calculated by using the formula:
Proportion = [MVA of a certain formation/total MVA of all 5 formations] × 100) in the 2 types of MVPs. C and D, Kaplan-Meier curves
showing cumulative PFS and OS of glioblastoma patients with different MVPs.
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Table 4 Differences between glioblastomas with type I and
type II MVPs
Type I
(n = 56)
Type II
(n = 22)
MGMT (%) a, median (95% CI) 26 (0-58) 31 (9-61)
Ki-67 (%) a, median (95% CI) 30 (3-79) 51 (7-88)
p53 (%) a, median (95% CI) 12 (0-84) 31 (6-92)
12-mo PFS rate (%) b 46.2 2.0
PFS (wk) b, median (95% CI) 47.6
(42.9-52.3)
30.0
(23.5-36.5)
12-mo OS rate (%) b 83.5 24.2
OS (wk) b, median (95% CI) 60.4
(57.6-63.2)
41.6
(36.0-47.2)
Abbreviations: MVP, microvascular pattern; CI, confidence interval;
PFS, progression-free survival; OS, overall survival.
a Mann-Whitney test.
b Log-rank test.
127Microvascular patterns in glioblastomaassessment of hotspot areas may account for the inconsis-
tency of these results, limiting the clinical use of histopath-
ologically evaluated vascular patterns as prognostic
indicators in patients with glioblastoma [10]. In our study,
we executed a multi-hotspot assessment by analyzing a
random sample of all of the preencoded hotspot areas.
This method may reduce interobserver variation and ensure
repeatability when assessing MVPs.
From a pathological perspective, VG and GVP possess a
large number of pericytes, which play critical roles in support
of vascular structure and function [23–25]. In addition, the
plasticity of tumor cells empowers them to mimic the
phenotypes and functions of ECs, thus leading to the
phenomenon of VM [13,20,21]. All these 3 microvascular
formations are quite different from the classic endothelium-
lined vessels morphologically and functionally, and thereby
may contribute to therapeutic resistance in glioblastoma.
Remarkably, recent studies have found that the presence of
pericytes and VM in a glioblastoma may be closely related to
the transdifferentiation of glioma stem cells (GSCs) [26–28].
These findings may indirectly explain why patients withTable 5 Multivariate analysis of cumulative PFS/OS of 78 patients w
PFS
HR (95% CI)
Age (≤58 y vs N58 y) 2.698 (1.547-4.708)
Preoperative KPS (≤80 vs N80) 0.520 (0.300-0.901)
Radiotherapy (yes vs no) –
Chemotherapy (b6 cycles vs ≥6 cycles) 0.217 (0.107-0.440)
MGMT (b30% vs ≥30%) 2.505 (1.463-4.290)
Ki-67 (≤30% vs N30%) –
p53 (≤10% vs N10%) 2.715 (1.503-4.903)
MVPs (type I vs type II) 4.573 (2.271-9.205)
Abbreviations: PFS, progression-free survival; OS, overall survival; HR, hazard r
performance status.tumor of type II MVP (predominantly contains VG, GVP,
and VM formations) had a poor prognosis and relapsed
shortly after surgery [29]. Moreover, controversy exists
regarding what type of microvascular formations transdiffer-
entiated GSCs would contribute to in glioblastoma. Some
findings suggested that transdifferentiation of GSCs into ECs
drives VM in glioblastoma [26,27], whereas results from one
other study indicated that GSCs may give rise to pericytes
and form a microvessel such as GVP [28]. In the current
study, we found that the proportion of VMs was significantly
lower than that of VGs and GVPs, which were rich in
pericytes. Accordingly, we speculate that the transdiffer-
entiation of GSCs into pericytes may be more critical in
mediating therapeutic resistance than it into ECs.
Nowadays several biomarkers, such as MGMT, Ki-67 and
p53, have been linked to patients prognosis in glioblastoma, and
recommended as routine laboratory examinations [15,16,30,31].
We compared these proteins' expression in glioblastoma with
type I and type II MVP. Statistical analysis disclosed significant
differences in expression of Ki-67 and p53 but not MGMT
between the 2 groups, indicating some potential relationships
of microvasculature heterogeneity with cell proliferation
and tumor suppressor deficiency. Hence, novel insights into
molecular mechanisms of angiogenesis in glioblastoma are
worth gaining.
In summary, although there is significant heterogeneity
among MVPs in glioblastoma, specific histopathologic and
statistical analyses of microvascular formations allowed us to
classify these tumors into 2 types. Patientswith tumor of type II
MVP, consisting mainly of VGs, GVPs, and VMs, have a
poorer clinical outcome than do those of type I MVP, which is
rich in MSs and VCs.Ethical declaration
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ethics committee of the Fujian Medical University.ith primary glioblastoma (Cox model)
OS
P HR (95% CI) P
b.001 3.241 (1.737-6.045) b.001
.020 0.367 (0.204-0.662) .001
.764 – .053
b.001 0.213 (0.091-0.496) b.001
.001 2.118 (1.219-3.679) .008
.086 – .811
.001 2.024 (1.138-3.600) .016
b.001 5.045 (2.396-10.620) b.001
atio; CI, confidence interval; MVP, microvascular pattern; KPS, Karnofsky
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